Previous
Previous

Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition on October 6-7th

Next
Next

Aqualung Therapeutics Plans A Phase 0 ARDS Trial for eNAMPT Monoclonal Antibody (Alt-100 mAb) Following Type B FDA Meeting